CelluTarget · Multifocal Motor Neuropathy · Clinical Trials
Phase 3
Active (not recruiting)
NCT06742190

Empasiprubart (ARGX-117)

Sponsored by argenx ↗
View on ClinicalTrials.gov ↗
Timeline
Study Dates
Start Date
November 2024
Est. Completion
—
Enrollment Target
100 participants
Status
Active (not recruiting)
Study Design
Primary Endpoint
Efficacy and safety of empasiprubart vs IVIg
Registry
ClinicalTrials.gov Record
Registry ID
NCT06742190
Direct Link
clinicaltrials.gov/NCT06742190 ↗
Related Treatment
Treatment Being Studied
Empasiprubart (ARGX-117) →